Clinical

Clinical
XyloCor advances its lead gene therapy candidate for refractory angina to Phase 2

Gene therapy digest – 2021 Gene therapy digest – 2021 XyloCor advances its lead gene therapy candidate for refractory angina to Phase 2 XC001 (AAV gene therapy; Phase 2) – XyloCor Therapeutics Phase 1 dose-escalation part of Phase 1/2 clinical […]

by Sandhya Ramalingam

Continue Reading
Clinical
ASC Therapeutics to codevelop first in-vivo gene therapy program for maple syrup urine disease

Gene therapy digest – 2021 Gene therapy digest – 2021 ASC Therapeutics to codevelop first in-vivo gene therapy program for maple syrup urine disease AAV gene therapy (Preclinical) – ASC Therapeutics ASC Therapeutics with University of Massachusetts Medical School (UMMS) […]

by Sandhya Ramalingam

Continue Reading